20th Apr 2016 16:00
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters.
1. | Name of the issuer
HIKMA PHARMACEUTICALS PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006).
(i) & (iii) |
3. | Name of person discharging managerial responsibilities/director
SAID DARWAZAH
| 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person
N/A
|
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial interest 1
3 ABOVE
| 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares
ORDINARY SHARES OF 10P EACH
|
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them
VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED
| 8. | State the nature of the transaction
PURCHASE OF 30,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE. |
9. | Number of shares, debentures or financial instruments relating to shares acquired
30,000 | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 0.01%
|
11. | Number of shares, debentures or financial instruments relating to shares disposed
N/A | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
N/A
|
13. | Price per share or value of transaction
£22.71p | 14. | Date and place of transaction
20 APRIL 2016, LONDON
|
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
13,145,267 (5.49%) COMPRISING:
DIRECTLY, INCLUDING CONNECTED PERSONS: 657,000 (0.27%)
INDIRECTLY THROUGH DARHOLD LIMITED: 12,488,267 (5.22%) | 16. | Date issuer informed of transaction
20 APRIL 2016 |
If a person discharging managerial responsibilities has been granted options by the issuer
complete the following boxes
17. | Date of grant
N/A | 18. | Period during which or date on which exercisable
N/A |
19. | Total amount paid (if any) for grant of the option
N/A | 20. | Description of shares or debentures involved (class and number)
N/A |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise
N/A | 22. | Total number of shares or debentures over which options held following notification
N/A |
23. | Any additional information
N/A | 24. | Name of contact and telephone number for queries
PETER SPEIRS 0207 399 2772
|
Name of authorised official of issuer responsible for making notification
Peter Speirs, Company Secretary
Date of notification 20 April 2016
|
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1) | An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. |
(2) | An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. |
(3) | An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. |
(4) | An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. |
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters.
1. | Name of the issuer
HIKMA PHARMACEUTICALS PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006).
(i) & (iii) |
3. | Name of person discharging managerial responsibilities/director
MAZEN DARWAZAH
| 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person
N/A
|
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial interest 1
3 ABOVE
| 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares
ORDINARY SHARES OF 10P EACH
|
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them
VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED
| 8. | State the nature of the transaction
PURCHASE OF 30,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE. |
9. | Number of shares, debentures or financial instruments relating to shares acquired
30,000 | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 0.01%
|
11. | Number of shares, debentures or financial instruments relating to shares disposed
N/A | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
N/A
|
13. | Price per share or value of transaction
£22.71p | 14. | Date and place of transaction
20 APRIL 2016, LONDON
|
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
7,193,979 (3.01%) COMPRISING:
DIRECTLY: 907,041 (0.38%)
INDIRECTLY THROUGH DARHOLD LIMITED: 6,286,938 (2.63%) | 16. | Date issuer informed of transaction
20 APRIL 2016 |
If a person discharging managerial responsibilities has been granted options by the issuer
complete the following boxes
17. | Date of grant
N/A | 18. | Period during which or date on which exercisable
N/A |
19. | Total amount paid (if any) for grant of the option
N/A | 20. | Description of shares or debentures involved (class and number)
N/A |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise
N/A | 22. | Total number of shares or debentures over which options held following notification
N/A |
23. | Any additional information
N/A | 24. | Name of contact and telephone number for queries
PETER SPEIRS 0207 399 2772
|
Name of authorised official of issuer responsible for making notification
Peter Speirs, Company Secretary
Date of notification 20 April 2016
|
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1) | An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. |
(2) | An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. |
(3) | An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. |
(4) | An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. |
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters.
1. | Name of the issuer
HIKMA PHARMACEUTICALS PLC | 2. | State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006).
(i) & (iii) |
3. | Name of person discharging managerial responsibilities/director
MOHAMMED 'ALI' AL-HUSRY
| 4. | State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person
N/A
|
5. | Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial interest 1
3 ABOVE
| 6. | Description of shares (including class), debentures or derivatives or financial instruments relating to shares
ORDINARY SHARES OF 10P EACH
|
7. | Name of registered shareholders(s) and, if more than one, the number of shares held by each of them
VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED
| 8. | State the nature of the transaction
PURCHASE OF 30,000 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE. |
9. | Number of shares, debentures or financial instruments relating to shares acquired
30,000 | 10. | Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 0.01%
|
11. | Number of shares, debentures or financial instruments relating to shares disposed
N/A | 12. | Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
N/A
|
13. | Price per share or value of transaction
£22.71p | 14. | Date and place of transaction
20 APRIL 2016, LONDON
|
15. | Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)
5,784,739 (2.42%) UNDER DYKB LIMITED COMPRISING:
DIRECTLY: 1,162,811 (0.49%)
INDIRECTLY THROUGH DARHOLD LIMITED: 4,621,928 (1.93%) | 16. | Date issuer informed of transaction
20 APRIL 2016 |
If a person discharging managerial responsibilities has been granted options by the issuer
complete the following boxes
17. | Date of grant
N/A | 18. | Period during which or date on which exercisable
N/A |
19. | Total amount paid (if any) for grant of the option
N/A | 20. | Description of shares or debentures involved (class and number)
N/A |
21. | Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise
N/A | 22. | Total number of shares or debentures over which options held following notification
N/A |
23. | Any additional information
N/A | 24. | Name of contact and telephone number for queries
PETER SPEIRS 0207 399 2772
|
Name of authorised official of issuer responsible for making notification
Peter Speirs, Company Secretary
Date of notification 20 April 2016
|
Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.
(1) | An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. |
(2) | An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. |
(3) | An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. |
(4) | An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. |
Related Shares:
Hikma Pharmaceuticals